Preclinical News and Research

RSS
Potential new treatment for sepsis and ARDS

Potential new treatment for sepsis and ARDS

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

Finerenone effective in heart failure patients with diabetes and/or chronic kidney disease

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

MACC1 gene can help predict better treatment options for patients with Klatskin carcinoma

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Four UC San Diego researchers selected to receive newly established NCI Outstanding Investigator Award

Four UC San Diego researchers selected to receive newly established NCI Outstanding Investigator Award

New study may lead to effective treatment to prevent common chemotherapy side effects in cancer patients

New study may lead to effective treatment to prevent common chemotherapy side effects in cancer patients

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Researchers identify druggable target to potentially root out colon cancer, end relapse

Researchers identify druggable target to potentially root out colon cancer, end relapse

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Soligenix obtains additional funding from NIAID to advance development of OrbeShield for GI ARS treatment

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

Symic receives $1.5M NIH Phase II SBIR grant to develop AVF therapeutic candidate

iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015

iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015

UH research points to promising target in treatment of pancreatic cancer

UH research points to promising target in treatment of pancreatic cancer

New research could potentially yield novel platform for cancer vaccines

New research could potentially yield novel platform for cancer vaccines

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.